Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
BlossomHill Therapeutics, Inc. (BLSM) is the issuer in an amended Schedule 13G reporting 1,493,740 shares beneficially owned by Vivo Innovation Fund II Holdings, L.P. and its general partner, Vivo Innovation II, LLC. Each reports ownership of 4.7% of the class. The shares are held of record by the fund, and both entities report sole voting and dispositive power over the same position. BlossomHill had 31,784,909 shares outstanding as of September 16, 2026.
Key Figures
Beneficially owned shares:1,493,740 sharesPercent of class:4.7%Shares outstanding:31,784,909 shares
3 metrics
Beneficially owned shares1,493,740 sharesReported by both Vivo Innovation Fund II Holdings, L.P. and its general partner, Vivo Innovation II, LLC; held of record by the fund.
Percent of class4.7%Reported by each reporting person.
Shares outstanding31,784,909 sharesBlossomHill shares outstanding as of September 16, 2026.
Key Terms
beneficially owned, sole voting power, sole dispositive power
3 terms
beneficially ownedregulatory
"Amount beneficially owned: 1,493,740 shares"
Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.
sole voting powerregulatory
"Sole voting power 1,493,740"
Sole voting power is the exclusive right to cast votes attached to a shareholder’s stock without needing approval from anyone else. Like holding the only remote control for a TV, it lets that holder decide corporate matters such as board members, mergers, and policy changes, making it important to investors because it concentrates control and can strongly influence a company’s strategy and the value of its shares.
sole dispositive powerregulatory
"Sole dispositive power 1,493,740"
Sole dispositive power is the exclusive legal authority to decide what happens to a security — for example, whether to sell, transfer, or retain shares — without needing anyone else’s permission. Investors care because it signals who truly controls the economic outcome of an investment: like holding the only key to a safe, the holder can realize gains or losses and may trigger regulatory reporting, insider rules, or influence over corporate ownership.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
How many BLSM shares does Vivo report beneficially owning?
Vivo Innovation Fund II Holdings, L.P. and its general partner, Vivo Innovation II, LLC, each report beneficial ownership of 1,493,740 BlossomHill common shares, or 4.7% of the class. The shares are held of record by the fund, so the two reports describe the same share position.
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
UNDER THE SECURITIES EXCHANGE ACT OF 1934
(Amendment No. 1)
BlossomHill Therapeutics, Inc.
(Name of Issuer)
Common Stock, par value $0.0001 per share
(Title of Class of Securities)
095130100
(CUSIP Number)
09/30/2026
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)
schemaVersion:
SCHEDULE 13G
CUSIP Number(s):
095130100
1
Names of Reporting Persons
Vivo Innovation Fund II Holdings, L.P.
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
1,493,740.00
6
Shared Voting Power
0.00
7
Sole Dispositive Power
1,493,740.00
8
Shared Dispositive Power
0.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
1,493,740.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
4.7 %
12
Type of Reporting Person (See Instructions)
PN
Comment for Type of Reporting Person: The number represents shares of common stock, par value $0.0001 per share (the "Common Stock") of BlossomHill Therapeutics, Inc. (the "Issuer"), which are held of record by Vivo Innovation Fund II Holdings, L.P. Vivo Innovation II, LLC is the general partner of Vivo Innovation Fund II Holdings, L.P.
The percent is based on 31,784,909 shares of the Issuer's Common Stock outstanding, as of September 16, 2026, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission ("SEC") on September 18, 2026.
SCHEDULE 13G
CUSIP Number(s):
095130100
1
Names of Reporting Persons
Vivo Innovation II, LLC
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
1,493,740.00
6
Shared Voting Power
0.00
7
Sole Dispositive Power
1,493,740.00
8
Shared Dispositive Power
0.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
1,493,740.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
4.7 %
12
Type of Reporting Person (See Instructions)
OO
Comment for Type of Reporting Person: The number represents shares of Common Stock of the Issuer, which are held of record by Vivo Innovation Fund II Holdings, L.P. Vivo Innovation II, LLC is the general partner of Vivo Innovation Fund II Holdings, L.P.
The percent is based on 31,784,909 shares of the Issuer's Common Stock outstanding, as of September 16, 2026, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on September 18, 2026.
SCHEDULE 13G
Item 1.
(a)
Name of issuer:
BlossomHill Therapeutics, Inc.
(b)
Address of issuer's principal executive offices:
10255 Science Center Drive, Suite 200, San Diego, California 92121
Item 2.
(a)
Name of person filing:
Vivo Innovation Fund II Holdings, L.P. and its General Partner Vivo Innovation II, LLC
(b)
Address or principal business office or, if none, residence:
192 Lytton Avenue, Palo Alto, CA 94301
(c)
Citizenship:
Vivo Innovation Fund II Holdings, L.P. is a Delaware limited partnership.
Vivo Innovation II, LLC is a Delaware limited liability company.
(d)
Title of class of securities:
Common Stock, par value $0.0001 per share
(e)
CUSIP No.:
095130100
Item 3.
If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)
Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)
Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)
Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)
Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)
An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)
An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)
A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)
A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)
A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)
A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
please specify the type of institution:
(k)
Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.
Ownership
(a)
Amount beneficially owned:
1,493,740 shares of the Issuer's Common Stock are held of record by Vivo Innovation Fund II Holdings, L.P. Vivo Innovation II, LLC is the general partner of Vivo Innovation Fund II Holdings, L.P.
(b)
Percent of class:
Vivo Innovation Fund II Holdings, L.P.: 4.7%
Vivo Innovation II, LLC: 4.7%
(c)
Number of shares as to which the person has:
(i) Sole power to vote or to direct the vote:
Vivo Innovation Fund II Holdings, L.P.: 1,493,740 shares
Vivo Innovation II, LLC: 1,493,740 shares
(ii) Shared power to vote or to direct the vote:
0
(iii) Sole power to dispose or to direct the disposition of:
Vivo Innovation Fund II Holdings, L.P.: 1,493,740 shares
Vivo Innovation II, LLC: 1,493,740 shares
(iv) Shared power to dispose or to direct the disposition of:
0
Item 5.
Ownership of 5 Percent or Less of a Class.
Ownership of 5 percent or less of a class
Item 6.
Ownership of more than 5 Percent on Behalf of Another Person.
Not Applicable
Item 7.
Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
Not Applicable
Item 8.
Identification and Classification of Members of the Group.
Not Applicable
Item 9.
Notice of Dissolution of Group.
Not Applicable
Item 10.
Certifications:
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
Vivo Innovation Fund II Holdings, L.P.
Signature:
/s/ Gaurav Aggarwal
Name/Title:
Gaurav Aggarwal/Managing Member of Vivo Innovation II, LLC, General Partner